IP Library › Granted Patent US 12,358,964
Granted Patent B2
US 12,358,964 · App. 18/323,124 · Granted Jul 15, 2025

Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same

Inventors: Yong Sung Kim (Suwon, KR); Keunok Jung (Suwon, KR); Ji Hee Ha (Daegu, KR); Dong Ki Choi (Daejeon, KR); Hye Ji Choi (Suwon, KR); Ye Jin Kim (Busan, KR)
Assignee: Ajou University Industry-Academic Cooperation Foundation
C07K14/5434A61K38/208C07K14/54C07K14/59A61K38/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,964
App. No.
18/323,124
Granted
Jul 15, 2025
Kind
B2
Abstract

The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.

Claims (21)

1. A method of reducing growth of a solid tumor, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin fragment crystallizable (Fc) pair and p40 and p35 subunits of IL-12, wherein

(a) the p40 and p35 subunits are linked separately to the first Fc region and the second Fc region, or to the second Fc region and the first Fc region, respectively;

(b) the p40 and p35 subunits are each linked to the N-terminus or C-terminus of the Fc regions; and

(c) CH3 domains of the first Fc region and the second Fc region each comprise one or more mutations promoting heterodimerization selected from the group consisting of:

(i) glutamic acid (E) substitution of the amino acid residue at position 360 in the CH3 domain of the first Fc region,

(ii) tryptophan (W) substitution of the amino acid residue at position 409 in the CH3 domain of the first Fc region, and

(iii) threonine (T) substitution of the amino acid residue at position 405 in the CH3 domain of the second Fc region and valine (V) substitution of the amino acid residue at position 399 in the CH3 domain of the second Fc region;

wherein the mutation positions are numbered according to the EU index.

2. The method of claim 1 , wherein the p40 and p35 subunits are each linked to the N-terminus of the Fc regions.

3. The method according to claim 2 , wherein the p40 or p35 subunit is linked to its corresponding Fc region by a linker.

4. The method according to claim 3 , wherein the p35 subunit is linked to its corresponding Fc region by a linker.

5. The method according to claim 4 , wherein the linker comprises a (G 4 S) 3 linker (SEQ ID NO: 21).

6. The method according to claim 1 , wherein each of the first Fc region and the second Fc region is from an Fc region selected from the group consisting of human IgG1, IgG2, IgG3, and IgG4.

7. The method according to claim 1 , wherein the first Fc region and the second Fc region are comprised in a whole antibody form selected from the group consisting of human IgG1, IgG2, IgG3, and IgG4.

8. The method according to claim 1 , wherein the CH3 domain of the second Fc region further comprises: arginine (R) substitution of the amino acid residue at position 347, wherein the position is numbered according to the EU index.

9. The method according to claim 8 , wherein the CH3 domains in the first Fc region and the second Fc region further comprise the following residues:

(i) cysteine (C) substitution at position 349 in the CH3 domain of the first Fc region; and

(ii) cysteine (C) substitution at position 354 in the CH3 domain of the second Fc region, wherein the positions are numbered according to the EU index.

10. The method according to claim 1 , wherein the IL-12 is human IL-12.

11. The method according to claim 1 , wherein the solid tumor is selected from the group consisting of colorectal cancer, melanoma, breast cancer, pancreatic cancer, kidney cancer, prostate cancer, ovarian cancer, small intestine cancer, esophageal cancer, cervical cancer, lung cancer, and lymphoma.

12. The method according to claim 1 , wherein the pharmaceutical composition is in combination with another solid tumor therapy.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2025
From: KIM, YONG SUNG; JUNG, KEUNOK; HA, JI HEE; CHOI, HYE JI; KIM, YE JIN; CHOI, DONG KI
To: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Reel/Frame 070103/0977 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2025
From: HA, JI HEE
To: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Reel/Frame 070105/0078 →
Priority Claims (2)
KR 10-2016-0101823 · Aug 10, 2016 · national
KR 10-2017-0101594 · Aug 10, 2017 · national
Continuity (3)
Division 16886184 · May 28, 2020
Division 16323839
Related Publication 20230416325A1 · Dec 28, 2023
References Cited (172)
US 4722848A · Paoletti et al. · 1988 [cited by applicant]
US 5173414A · Lebkowski et al. · 1992 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5807706A · Carter et al. · 1998 [cited by applicant]
US 5849589A · Tedder et al. · 1998 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6838260B2 · Gillies et al. · 2005 [cited by applicant]
US 6864235B1 · Turley et al. · 2005 [cited by applicant]
US 7226998B2 · Gillies et al. · 2007 [cited by applicant]
US 7576193B2 · Gillies et al. · 2009 [cited by applicant]
US 7695936B2 · Carter et al. · 2010 [cited by applicant]
US 7879319B2 · Gillies et al. · 2011 [cited by applicant]
US 7943743B2 · Korman et al. · 2011 [cited by applicant]
US 7951917B1 · Arathoon et al. · 2011 [cited by applicant]
US 8034630B2 · Terashima et al. · 2011 [cited by applicant]
US 8044022B2 · Kolodka et al. · 2011 [cited by applicant]
US 8163498B2 · Fujita · 2012 [cited by applicant]
US 8192744B2 · Stromblad et al. · 2012 [cited by applicant]
US 8592562B2 · Kannan et al. · 2013 [cited by applicant]
US 8674083B2 · Presta · 2014 [cited by applicant]
US 8679785B2 · Carter et al. · 2014 [cited by applicant]
US 8765412B2 · Arathoon et al. · 2014 [cited by applicant]
US 8802093B2 · Johnson et al. · 2014 [cited by applicant]
US 8871912B2 · Davis et al. · 2014 [cited by applicant]
US 8945571B2 · Mössner et al. · 2015 [cited by applicant]
US 8969526B2 · Baehner et al. · 2015 [cited by applicant]
US 9217016B2 · Panitch et al. · 2015 [cited by applicant]
US 9248182B2 · De Kruif et al. · 2016 [cited by applicant]
US 9447159B2 · Ast et al. · 2016 [cited by applicant]
US 9493578B2 · Lazar et al. · 2016 [cited by applicant]
US 9505848B2 · Davis et al. · 2016 [cited by applicant]
US 9562109B2 · Von Kreudenstein et al. · 2017 [cited by applicant]
US 9637557B2 · Scheer et al. · 2017 [cited by applicant]
US 9714291B2 · Niwa et al. · 2017 [cited by applicant]
US 9751919B2 · Saward et al. · 2017 [cited by applicant]
US 9795686B2 · Lee et al. · 2017 [cited by applicant]
US 9951145B2 · Kim et al. · 2018 [cited by applicant]
US 10011644B2 · Rueger et al. · 2018 [cited by applicant]
US 10047167B2 · Demarest et al. · 2018 [cited by applicant]
US 10696722B2 · Kim et al. · 2020 [cited by applicant]
US 10767760B2 · Ando · 2020 [cited by applicant]
US 11078249B2 · Kim et al. · 2021 [cited by applicant]
US 11787864B2 · Cheung et al. · 2023 [cited by applicant]
US 20020055488A1 · Wessels et al. · 2002 [cited by applicant]
US 20070259380A1 · Sumida et al. · 2007 [cited by applicant]
US 20100015089A1 · Gillies et al. · 2010 [cited by applicant]
US 20100256339A1 · Bossenmaier et al. · 2010 [cited by applicant]
US 20100286374A1 · Kannan et al. · 2010 [cited by applicant]
US 20110054151A1 · Lazar et al. · 2011 [cited by applicant]
US 20120149876A1 · Von Kreudenstein et al. · 2012 [cited by applicant]
US 20130039913A1 · Labrijn et al. · 2013 [cited by applicant]
US 20140072579A1 · De Kruif et al. · 2014 [cited by applicant]
US 20140079689A1 · Elliott et al. · 2014 [cited by applicant]
US 20160046727A1 · Labrijn et al. · 2016 [cited by applicant]
US 20160194389A1 · Regula et al. · 2016 [cited by applicant]
US 20170056522A1 · Gerdes et al. · 2017 [cited by applicant]
US 20170198038A1 · Gauthier et al. · 2017 [cited by applicant]
US 20170260252A1 · Scheer et al. · 2017 [cited by applicant]
US 20170342128A1 · Auer et al. · 2017 [cited by applicant]
US 20170342167A1 · Moessner et al. · 2017 [cited by applicant]
US 20170342168A1 · Schlothauer · 2017 [cited by applicant]
US 20180118828A1 · Bernett et al. · 2018 [cited by applicant]
US 20180237541A1 · Kim et al. · 2018 [cited by applicant]
US 20180258386A1 · Rafii et al. · 2018 [cited by applicant]
US 20180282386A1 · Vallera et al. · 2018 [cited by applicant]
US 20180340014A1 · Viney et al. · 2018 [cited by applicant]
US 20180346600A1 · Kim et al. · 2018 [cited by applicant]
US 20190169252A1 · Kim et al. · 2019 [cited by applicant]
US 20190185584A1 · Scheer et al. · 2019 [cited by applicant]
US 20190218282A1 · Dengl et al. · 2019 [cited by applicant]
US 20200216509A1 · Bernett et al. · 2020 [cited by applicant]
US 20200283524A1 · Xu et al. · 2020 [cited by applicant]
US 20200299347A1 · Gigout et al. · 2020 [cited by applicant]
US 20200362005A1 · Kim et al. · 2020 [cited by applicant]
US 20220119533A1 · Cheung et al. · 2022 [cited by applicant]
US 20220267460A1 · Lansing et al. · 2022 [cited by applicant]
CN 104955953A · 2015 [cited by applicant]
EP 2691417B1 · 2018 [cited by applicant]
JP 2001525423 · 2001 [cited by applicant]
JP 2013539787A · 2013 [cited by applicant]
JP 2018093879A · 2018 [cited by applicant]
JP 2019536734A · 2019 [cited by applicant]
KR 1020150008012A · 2015 [cited by applicant]
WO WO1996027011A1 · 1996 [cited by applicant]
WO WO1999029732A2 · 1999 [cited by applicant]
WO WO2009089004A1 · 2009 [cited by applicant]
WO WO2010088444A1 · 2010 [cited by applicant]
WO WO2011131746A2 · 2011 [cited by applicant]
WO WO2012025530A1 · 2012 [cited by applicant]
WO WO2012032080A1 · 2012 [cited by applicant]
WO WO201251147A1 · 2012 [cited by applicant]
WO WO2012107417A1 · 2012 [cited by applicant]
WO WO2013012733A1 · 2013 [cited by applicant]
WO WO2013053775A1 · 2013 [cited by applicant]
WO WO2014023679A1 · 2014 [cited by applicant]
WO WO2014084607A1 · 2014 [cited by applicant]
WO WO2014144722A2 · 2014 [cited by applicant]
WO WO2014145016A2 · 2014 [cited by applicant]
WO WO2014145907A1 · 2014 [cited by applicant]
WO WO2015150447A1 · 2015 [cited by applicant]
WO WO2017027422A1 · 2017 [cited by applicant]
WO WO2017065484A1 · 2017 [cited by applicant]
WO WO2018030806A1 · 2018 [cited by applicant]
WO WO2018044105A1 · 2018 [cited by applicant]
WO WO2018071919A1 · 2018 [cited by applicant]
WO WO2018152518A1 · 2018 [cited by applicant]
WO WO2018177966A1 · 2018 [cited by applicant]
WO WO2018208448A1 · 2018 [cited by applicant]
WO WO2018237159A1 · 2018 [cited by applicant]
WO WO2019051308A1 · 2019 [cited by applicant]
WO WO2019077092A1 · 2019 [cited by applicant]
WO WO2020072821 · 2020 [cited by applicant]
WO WO2020086758A1 · 2020 [cited by applicant]
Atwell et al. (1997) “Stable Heterodimers from Remodeling the Domain Interface of a Homodimer using a Phage Display Library”, J. Mol. Biol., 270(1):26-35. [cited by applicant]
Baek et al. (2014) “Construction of a Large Synthetic Human Fab Antibody Library on Yeast Cell Surface by Optimized Yeast Mating,” J. Microbiol. Biotechnol. 24(3):408-420. [cited by applicant]
Brar et al. (2014) “Genomic Evolution of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Isolates Revealed by Deep Sequencing,” PLoS One 9(4):e88807 (12 pages). [cited by applicant]
Brekke et al. (1994) “Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis,” Eur. J. Immunol. 24:2542-2547. [cited by applicant]
Chan et al. (2010) “Therapeutic antibodies for autoimmunity and inflammation,” Nature Reviews Immunology 10:301-316. [cited by applicant]
Choi et al. (2013) “A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor Activity,” Mol Cancer Ther. 12(12):2748-2759. [cited by applicant]
Choi et al. (2015) “Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation,” Mol Immunol 65:377-383. [cited by applicant]
Choi et al. (2015) “Engineering of Immunoglobin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening,” PLoS One 10(12):e0145349:1-20. [cited by applicant]
Cunningham et al. (1969) “Subgroups of Amino Acid Sequences in the Variable Regions of Immunoglobulin Heavy Chains,” Proc. Natl. Acad. Sci. USA 64(3):997-1003. [cited by applicant]
Davis et al. (2010) “SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) C [cited by applicant]
De et al. (2015) “Estimation of D-Arabinose by Gas Chromatography/Mass Spectrometry as Surrogate for Mycobacterial Lipoarabinomannan in Human Urine,” PLoS One 10(12):e0144088, 17 pages. [cited by applicant]
Doctoral Thesis of Hye-Ji Choi at The Graduate School of Ajou University Department of Molecular Science and Technology, “Development of heterodimeric Fc variants for bispecific antibody platform technology,” Aug. 2015 … [cited by applicant]
Extended European Search Report, European Application No. 17839824.4, dated Feb. 18, 2020 (13 pages). [cited by applicant]
Feng et al. (2011) “Design, Expression and Characterization of a Soluble Single-Chain Functional Human Neonatal Fc Receptor,” Protein Expression and Purification 79(1):66-71. [cited by applicant]
Gafner et al. (2006) “An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties,” International Journal of Cancer 119(9):2205-2212. [cited by applicant]
GenBank Accession No. NP 000873.2. [cited by applicant]
GenBank Accession No. NP 002178.2. [cited by applicant]
Gillies et al. (1998) “Antibody-IL-12 Fusioin Proteins Are Effective in SCID Mouse Models of Prostate and Colon Carcinoma Metastases,” Journal of Immunology, 160(12):6195-6203. [cited by applicant]
Gunasekaran et al. (2010) “Enhancing Antibody Fc Heterodimer Formation Through Electrostatic Steering Effects: Applications to Bispecific Molecules and Monovalent IgG,” J. Biol. Chem. Papers in Press Manuscript M110.117… [cited by applicant]
Gutierrez et al. (2023) “An Optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses,” Med 4:1-15 (32 pages). [cited by applicant]
Ha et al. (2016) “Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins,” Front. Immunol. 7(394)1-16. [cited by applicant]
Holliger et al. (2005) “Engineered antibody fragments and the rise of single domains,” Nature Biotechnology 23(9):1126-1136. [cited by applicant]
Hu et al. (2013) “Porcine Reproductive and Respiratory Syndrome Virus Vaccines: Current Status and Strategies to a Universal Vaccine,” Transboundary and Emerging Diseases 61:109-120. [cited by applicant]
Idusogie et al. (2000) “Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc,” Journal of Immunology, 164(8):4178-4184. [cited by applicant]
International Search Report and Written Opinion for PCT/KR2017/008676, dated Nov. 15, 2017 (18 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2019/057721, dated Jan. 15, 2020 (25 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2021/028701, dated Jul. 8, 2021 (11 pages). [cited by applicant]
International Search Report for PCT/KR2017/008676, dated Nov. 15, 2017 (3 pages). [cited by applicant]
Isaacs et al. (1998) “Therapy with Monoclonal Antibodies. II. The Contribution of Fcy Receptor Binding and the Influence of C [cited by applicant]
Jung et al. (2018) “Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells,” Oncoimmunology, 7(7):eI438800 (13 pages). [cited by applicant]
Kim et al. 2007 “Comparative Analyses of Complex Formation and Binding Sites between Human Tumor Necrosis Factor-alpha and its Three Antagonists Elucidate their Different Neutralizing Mechanisms,” J. Mol. Biol. 374:1374… [cited by applicant]
Klein et al. (2012) “Progress in overcoming the chain association issue in bispecific; heterodimeric IgG antibodies,” mAbs 4(6):653-663. [cited by applicant]
Liu et al. (2017) “Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds,” Frontiers in Immunology 8(38) (15 pages). [cited by applicant]
Lo et al. (2017) “Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice,” J. Biol. Chem. 292(9):3900-3908. [cited by applicant]
Low et al. (2005) “Oral and pulmonary Delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis,” Human Reproduction 20(7):1805-1813. [cited by applicant]
Lu et al. (2004) “Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody,” J … [cited by applicant]
McBurney et al. (2009) “Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines,” Vaccine 2… [cited by applicant]
Merchant et al. (1998) “An efficient route to human bispecific IgG,” Nature Biotechnology 16:677-681. [cited by applicant]
Miller et al. (2003) “Design, Construction, and In Vitro Analyses of Multivalent Antibodies,” J Immunol 170(9):4854-4861. [cited by applicant]
Milstein et al. (1983) “Hybrid Hybridomas and Their Use in immunohistochemistry,” Nature 305:537-540. [cited by applicant]
Moore et al. (2011) “A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens,” mAbs 3(6):546-557. [cited by applicant]
Müller et al. (2013) “High-resolution structures of the IgM Fc domains reveal principles of its hexamer formation,” PNAS 110(25):10183-10188. [cited by applicant]
Renukaradhya et al. (2015) “Live porcine reproductive and respiratory syndrome virus vaccines: Current status and future direction,” Vaccine 33:4069-4080. [cited by applicant]
Ridgway et al. (2014) “‘Knobs-into-Holes’ engineering of antibody C [cited by applicant]
Schlothauer et al. (2016) “Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions,” Protein Engineering, Design & Selection 29(10):457-466. [cited by applicant]
Shields et al. (2001) “High Resolution Mapping of the Binding Site of Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR, ” The Journal of Biological Chemistry … [cited by applicant]
Strop et al. (2012) “Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair,” J. Mol. Biol. 420:204-219. [cited by applicant]
Tao et al. (1993) “Structural Features of Human Immunoglobulin G that Determine Isotype-specific Differences in Complement Activation,” J. Exp. Med. 178:661-667. [cited by applicant]
Von Kreudenstein et al. (2013) “Improving biophysical properties of a bispecific antibody scaffold to aid developability,” mAbs 5(5):646-654. [cited by applicant]
Von Kreudenstein et al. (2014) “Protein engineering and the use of molecular modeling and simulation: The case of heterodimeric Fc engineering,” Methods 65:77-94. [cited by applicant]
Vu et al. (2015) “A Synthetic Porcine Reproductive and Respiratory Syndrome Virus Strain Confers Unprecedented Levels of Heterologous Protection,” Journal of Virology 89(23):12070-12083. [cited by applicant]
Wang et al. (2018) “IgG Fc engineering to modulate antibody effector functions,” Protein Cell 9(1):63-73. [cited by applicant]
Xie et al. (2005) “A new format of bispecific antibody highly efficient heterodimerization, expression and tumor cell lysis,” Journal of Immunological Methods 296:95-101. [cited by applicant]
Nikitovic et al. (2018) “Proteoglycans-Biomarkers and Targets in Cancer Therapy,” frontiers in Endocrinology 9(69) (8 pages). [cited by applicant]
Fast et al. (2009) “Physical Instability of a Therapeutic Fc Fusion Protein: Domain Contributions to Conformational and Colloidal Stability,” Biochemistry 48:11724-11736. [cited by applicant]
Shukla et al. 2007 “Protein aggregation kinetics during Protein A chromatography Case study for an Fc fusion protein,” Journal of Chromatography A 1171:22-28. [cited by applicant]
Shukla et al. (2015) “Viral clearance for biopharmaceutical downstream processes,” Pharm. Bioprocess 3(2):127-138. [cited by applicant]